SunWay Biotech Co., LTD. (TPEX:1271)
Taiwan
· Delayed Price · Currency is TWD 57.40
-0.20 (-0.35%)
May 14, 2025, 12:41 PM CST
SunWay Biotech Co., LTD. Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 970.18 | 571.11 | 425.35 | 380.43 | 314.48 | Upgrade
|
| Revenue Growth (YoY) | 69.88% | 34.27% | 11.81% | 20.97% | 82.64% | Upgrade
|
| Cost of Revenue | 425.14 | 334.45 | 275.46 | 109.32 | 106.02 | Upgrade
|
| Gross Profit | 545.04 | 236.67 | 149.89 | 271.11 | 208.46 | Upgrade
|
| Selling, General & Admin | 350.04 | 177.4 | 111.03 | 60 | 49.59 | Upgrade
|
| Research & Development | 54.02 | 6.21 | - | 43.38 | 32.99 | Upgrade
|
| Operating Expenses | 404.06 | 184.57 | 110.66 | 103.82 | 82.58 | Upgrade
|
| Operating Income | 140.98 | 52.1 | 39.23 | 167.29 | 125.88 | Upgrade
|
| Interest Expense | -5.54 | -2.09 | -1.15 | -0.09 | -0.2 | Upgrade
|
| Interest & Investment Income | 2.99 | 1.79 | 0.23 | 0.06 | 0.04 | Upgrade
|
| Earnings From Equity Investments | -0.04 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 2.62 | 3.29 | 1.7 | -0.12 | -0.06 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.02 | 1.14 | -0.38 | 3.21 | 0.14 | Upgrade
|
| EBT Excluding Unusual Items | 142.02 | 56.23 | 39.63 | 170.35 | 125.81 | Upgrade
|
| Asset Writedown | - | - | - | -0.14 | -0.11 | Upgrade
|
| Other Unusual Items | 0.07 | -0.31 | - | - | - | Upgrade
|
| Pretax Income | 142.09 | 55.92 | 39.63 | 170.21 | 125.7 | Upgrade
|
| Income Tax Expense | 23.53 | 9.79 | 8.29 | 0.49 | - | Upgrade
|
| Earnings From Continuing Operations | 118.56 | 46.13 | 31.34 | 169.72 | 125.7 | Upgrade
|
| Minority Interest in Earnings | 0.01 | -0.04 | -1.3 | -0.96 | 0.02 | Upgrade
|
| Net Income | 118.57 | 46.09 | 30.04 | 168.76 | 125.71 | Upgrade
|
| Net Income to Common | 118.57 | 46.09 | 30.04 | 168.76 | 125.71 | Upgrade
|
| Net Income Growth | 157.26% | 53.42% | -82.20% | 34.24% | 228.78% | Upgrade
|
| Shares Outstanding (Basic) | 60 | 31 | 20 | 34 | 32 | Upgrade
|
| Shares Outstanding (Diluted) | 60 | 31 | 20 | 34 | 32 | Upgrade
|
| Shares Change (YoY) | 97.22% | 51.54% | -41.13% | 5.76% | -3.72% | Upgrade
|
| EPS (Basic) | 1.96 | 1.51 | 1.49 | 5.01 | 3.96 | Upgrade
|
| EPS (Diluted) | 1.96 | 1.50 | 1.48 | 4.92 | 3.87 | Upgrade
|
| EPS Growth | 30.26% | 1.33% | -69.80% | 26.90% | 242.60% | Upgrade
|
| Free Cash Flow | 40.73 | 9.75 | 42.58 | 151.05 | 180.3 | Upgrade
|
| Free Cash Flow Per Share | 0.67 | 0.32 | 2.11 | 4.40 | 5.55 | Upgrade
|
| Dividend Per Share | 1.330 | 0.983 | 3.186 | 4.278 | 2.754 | Upgrade
|
| Dividend Growth | 35.24% | -69.14% | -25.52% | 55.36% | - | Upgrade
|
| Gross Margin | 56.18% | 41.44% | 35.24% | 71.26% | 66.29% | Upgrade
|
| Operating Margin | 14.53% | 9.12% | 9.22% | 43.97% | 40.03% | Upgrade
|
| Profit Margin | 12.22% | 8.07% | 7.06% | 44.36% | 39.98% | Upgrade
|
| Free Cash Flow Margin | 4.20% | 1.71% | 10.01% | 39.70% | 57.34% | Upgrade
|
| EBITDA | 188.21 | 63.78 | 44.22 | 177.12 | 136.89 | Upgrade
|
| EBITDA Margin | 19.40% | 11.17% | 10.40% | 46.56% | 43.53% | Upgrade
|
| D&A For EBITDA | 47.23 | 11.69 | 4.99 | 9.83 | 11.01 | Upgrade
|
| EBIT | 140.98 | 52.1 | 39.23 | 167.29 | 125.88 | Upgrade
|
| EBIT Margin | 14.53% | 9.12% | 9.22% | 43.97% | 40.03% | Upgrade
|
| Effective Tax Rate | 16.56% | 17.51% | 20.91% | 0.29% | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.